Previous 10 | Next 10 |
Horizon Therapeutics ( HZNP ) Q2 results : More news on: Horizon Therapeutics Public Limited Company, Read more ...
Aerpio Pharmaceuticals (NASDAQ: ARPO ) +61% on announcing a second clinical trial with funding from MTEC. More news on: Aerpio Pharmaceuticals, Inc., Whiting Petroleum Corporation, Hepion Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Horizon Therapeutics (NASDAQ: HZNP ) : Q2 Non-GAAP EPS of $0.40 beats by $0.04 ; GAAP EPS of -$0.42 misses by $0.41 . More news on: Horizon Therapeutics Public Limited Company, Earnings news and commentary, Healthcare stocks news, Read more ...
-- Record Second-Quarter 2020 Net Sales of $462.8 Million Increased 44 Percent; Second-Quarter 2020 GAAP Net Loss of $80.0 Million; Adjusted EBITDA of $190.7 Million -- -- Quarterly Orphan Segment Net Sales Increased 87 Percent to $379.3 Million; Now Represents More Than 80 Percent o...
-- 89 percent of patients who received placebo during the OPTIC Phase 3 clinical trial and then received TEPEZZA in the OPTIC-X extension trial achieved clinically significant proptosis reduction with an average of 12 months of disease, compared with six months in OPTIC -- -- Majority ...
-- Randomized controlled trial will add to results from prior open-label trial and in-practice case series -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company has reached target patient enrollment for its M ethotrexate to I ncrease R esponse R ates in Pat...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its second-quarter 2020 financial results will be released on Wednesday, Aug. 5, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating ...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a permanent, product-specific Healthcare Common Procedure Coding System (HCPCS) J-code (J3241) for TEPEZZA ® (teprotumumab-trbw), the first and only FDA-ap...
Thinly traded nano cap Acer Therapeutics (NASDAQ: ACER ) jumps 20% premarket on modestly higher volume in reaction to results from a food effect study in 36 healthy volunteers that showed administration with ACER-001 in a fasted state increased systemic exposure of phenylbutyra...
CHARLOTTESVILLE, Va. , July 9, 2020 /PRNewswire/ -- HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) to discover and develop novel therapeutics for g...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...